Publications by authors named "A Guignard"

Pertussis resurgence has been documented even in countries with high pediatric vaccine coverage. The proportion of isolates not expressing pertactin (PRN) has increased in several countries where acellular pertussis (aP) vaccines are used. We systematically reviewed published literature up to July 2023 on PRN-negative isolates in MEDLINE and Embase with no geographical limitations, complemented with a gray literature search.

View Article and Find Full Text PDF
Article Synopsis
  • South Korea introduced a combined vaccine for diphtheria, tetanus, pertussis, poliomyelitis, and type b invasive infections (DTaP-IPV/Hib) for infants starting at 2 months old in 2018, and a study evaluated its safety from 2018 to 2022.
  • In total, 646 out of 660 infants were monitored for 30 days after vaccination, and 22.1% experienced adverse events (AEs), primarily mild issues like fever, injection site swelling, and irritability.
  • The study found that most AEs were not serious, with very few leading to serious adverse events (SAEs), confirming that the DTaP-IPV/H
View Article and Find Full Text PDF

Background: Total hip arthroplasty (THA) after acetabular fracture is typically performed months or years later for posttraumatic arthritis after initial conservative treatment. But THA can be performed earlier after open reduction and internal fixation (ORIF) of the fracture. The aim of this study was to determine which strategy is best.

View Article and Find Full Text PDF

Despite vaccination programs, pertussis has been poorly controlled, especially among older adults in Australia. This longitudinal, retrospective, observational study aimed to estimate the incidence and risk factors of pertussis among persons ≥50 years of age in Australia in the primary care setting, including those with underlying chronic obstructive pulmonary disease (COPD) or asthma. We used the IQVIA general practitioner electronic medical record database to identify patients ≥50 years of age with a clinical diagnosis of pertussis during 2015-2019.

View Article and Find Full Text PDF

Following the approval of for the immunization of girls and women in China against high-risk human papillomavirus types 16 and 18, a non-interventional post-authorization safety study was performed. A multi-center prospective cohort study assessed safety following vaccination of Chinese girls and women aged 9-45 years between 31 May 2018 and 3 December 2020. Adverse events following immunization (AEFIs), potential immune-mediated diseases (pIMDs), and pregnancy-related outcomes were collected up to 12 months from the third immunization or 24 months from the first immunization, whichever came first.

View Article and Find Full Text PDF